News
MedPage Today on MSN2d
Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data
Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...
Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...
New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...
Health and Me on MSN2d
Could This New Alzheimer’s Drug Buy Patients Four More Good Years? Here Is What We Know
A new Alzheimer’s drug, lecanemab, may slow disease progression and offer patients up to four extra years of stable health.
Patients could have four more years of good health on the new drug while trial users have seen cognitive improvements too ...
3don MSN
Alzheimer’s ‘wonder drug’ slows progression of disease by four years - and could even reverse it
An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers ...
Groundbreaking new Alzheimer’s treatment could give patients four years of better health. Patients who participated in the ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...
Live Science on MSN6d
Dementia: Facts about Alzheimer's and other forms of dementia
Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...
Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback